ロード中...
The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
BACKGROUND: Nowadays, patients with EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitive advanced non-small cell lung cancer (NSCLC) receive EGFR-TKIs as first-line treatment. We aimed to analyze the relationship between preliminary efficacy (tumor shrinkage within 1 month) and progression-free survi...
保存先:
| 出版年: | Ann Transl Med |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AME Publishing Company
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6545314/ https://ncbi.nlm.nih.gov/pubmed/31205913 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.06 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|